Interleukin-2 receptor antibody induction with early low dose tacrolimus preserves post-liver transplant renal function in at risk individuals

Renal dysfunction post liver transplantation (LT) is common. We report our real-world experience of IL2Ra induction with immediate exposure to reduced dose tacrolimus used for patients chronic kidney disease (CKD) and evolving acute injury (AKI). A single-centre retrospective analysis elective adult LT from 1/1/17 31/12/17. The primary outcome measure was increase in CKD stage at month 6 post-LT, secondary early biopsy proven rejection (BPAR). 161 were included: 17 planned-IL2Ra CKD; 38 unplanned-IL2Ra AKI; 106 standard immunosuppression. group had lower trough levels till 3 post-LT. Patients receiving did not have an increased risk class (aOR 0.95, 95% CI 0.34–2.75, P = 0.92), or BPAR 0.53, 0.19–1.32, 0.19). can be given AKI no greater attrition renal function months when compared IS. Longer-term data required, however this regimen considered high recipients AKI.